1.       WHO Policy Perspectives on Medicines: WHO Medicines Strategy: 2000 – 2003, No. 1. December 2000.
WHO, Geneva http://www.who.int/medicines/strategy/whozip16e/begin.htm

2.       Report on the Global HIV/AIDS Epidemic 2002. UNAIDS at Barcelona, 2002.

http://www.unaids.org/barcelona/presskit/report.html

3.       Strategic Framework to decrease the Burden of TB/HIV". WHO/CDS/TB/2002.296 and

WHO/HIV_AIDS/2002.2. WHO, Geneva.

4.       http://www.who.int/gtb/publications/tb_hiv/2002-296_index.htm

5.       Fact Sheet 2002: The Impact of HIV:

http://www.unaids.org/barcelona/presskit/factsheets/FSimpact_en.htm

6.       AIDS Epidemic Update – December 2001. WHO/UNAIDS 2001. http://www.unaids.org/epidemic_update/report_dec01/index.html#full

7.       Global Plan to Stop TB (2001-2005): http://www.stoptb.org/GPSTB/default.asp

8.       Global TB Control. WHO Report 2001. WHO/CDS/TB/2001.287. WHO, Geneva. http://www.who.int/gtb/publications/globrep01/download.html

9.       TB/HIV and Development: Technical Resources. http://www.stoptb.org/Working_Groups/TBHIV/default.asp

10.   Prospectus: Global TB Drug Facility: a Global Mechanism to Ensure an Uninterrupted Access to Quality
TB Drugs for DOTS implementation. WHO/CDS/STB/2000.10a.

http://www.stoptb.org/GDF/whatis/docs/GDF-prospectus.pdf

11.   Brochure: Global TB Drug Facility: What is the Global TB Drug Facility? WHO/CDS/STB/2000.10b. http://www.stoptb.org/GDF/whatis/docs/GDF-Brochure.PDF

12.   Brochure: The DOTS-Plus Strategy for MDR-TB and Green Light Committee: Improving Access to Second-Line

Anti-TB Drugs. WHO/CDS/TB/2000.283.

      http://www.who.int/gtb/policyrd/PDF/DOTSGLC.pdf

13.   TB Literature: http://www.who.int/gtb/publications/

14.   TB Literature by Subject. http://www.who.int/gtb/publications/refsubject.html

15.   WHO Expert Committee on Malaria. 20^th Report.2000. WHO TRS 892; WHO Geneva. http://mosquito.who.int
/docs/ecr20.pdf

16.   12^th Expert Committee on the Selection and Use of Essential Medicines, 15-19 April 2002.

http://www.who.int/medicines/organization/par/edl/eml.shtml

17.   WHO Policy Perspectives on Medicines: The Selection of Essential Medicines. No. 4. June 2002. WHO, Geneva.

http://www.who.int/medicines/library/edm_general/6pagers/ppm04eng.pdf

HIV/AIDS

18.   Scaling Up Anti-Retroviral Therapy in Resource-Limited Settings: Guidelines for Public Health Approach. WHO, April 2002.

http://www.who.int/HIV_AIDS/HIV_AIDS_Care/
Scaling_Up_ARV_Guidelines_Final_E.pdf

19.   Overview of HIV Diagnostic Technologies.

http://www.who.int/bct/Main_areas_of_work/BTS/HIV_Diagnostics/
Overview_of_HIV_Diagnostic_Tech.htm

20.   Guidelines for Using HIV Testing Technologies in Surveillance: Selection, Evaluation, and Implementation/Pautas
para aplicar las técnicas de los exámenes de detección del VIH a la vigilancia de la infección: Selección, evaluación
y uso. UNAIDS/CDC/USAID/WHO 2001.

WHO/CDS/CSR/EDC/2001.16 and UNAIDS/01.22E

http://www.who.int/emc-documents/aids_hiv/whocdscsredc200116c.html

21.   Laboratory Monitoring of ARV Therapy. http://www.who.int/bct/Main_areas_of_work/BTS/HIV_Diagnostics/
Laboratory_monotoring_for_ARV_Therapy.htm

22.   HIV Test Kits Evaluation. http://www.who.int/bct/Main_areas_of_work/BTS/HIV_Diagnostics/
HIV_Test_Kit_Evaluation.htm

23.   Guidelines for the Management of Sexually Transmitted Infections. WHO, 2001. WHO/HIV_AIDS/2001.01 and
WHO/RHR/01.10

http://www.who.int/HIV_AIDS/STIcasemanagement/STIManagemntguidelines/
who_hiv_aids_2001.01/index.htm

24.   Prevention of Mother-to-Child Transmission of HIV: Selection and Use of Nevirapine.
Technical Notes . WHO/HIV_AIDS/2001.03 and WHO/RHR/01.21. http://www.who.int/HIV_AIDS/MTCT/index.htm

25.   Developing HIV/AIDS Treatment Guidelines. Geneva, UNAIDS, 1999. UNAIDS Best Practice Collection, May 1999. http://www.unaids.org/publications/order.html

26.   WHO Model Prescribing Information: Drugs Used in HIV-related Illnesses. Geneva, WHO, 1999. WHO/DMP/DSI/99.2.

http://www.who.int/medicines/library/qsm/who-dmp-dsi-99-2/who-dmp-dsi-99-2.htm

27.   Nine Guidance Modules on Antiretroviral Treatments. (Only module 3, 7, 8 and 9 are still recommended)
WHO/ASD/98.1, UNAIDS/98.7. UNAIDS/WHO. June 1998. http://www.who.int/HIV_AIDS/antiretroviral_modules/
indexar.htm

28.   Guidelines on Standard Treatments and Essential Drugs for HIV-related Conditions - Access to HIV-related
Drugs. Geneva, WHO, 1997. DAP/97.9.

Tuberculosis

29.   An Expanded DOTS Framework for Effective Tuberculosis Control. WHO/CDS/TB/2002.297.

http://www.who.int/gtb/dots/2002-297.htm

30.   DOTS-Plus for Multi-Drug Resistant Tuberculosis (MDR-TB) http://www.who.int/gtb/policyrd/DOTSplus.htm

31.   DOTS-Plus and the Greenlight Committee.

http://www.who.int/gtb/policyrd/PDF/DOTSGLC.pdf

32.   Tuberculosis Diagnostics Initiative. http://www.who.int/tdr/diseases/tb/tbdi.htm

33.   The Rationale for Recommending Fixed-Dose Combination Tablets for Treatment of Tuberculosis. Bulletin of the World Health Organization, 2001, 79 (1). http://www.who.int/bulletin/pdf/2001/issue1/bu0435.pdf

34.   Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of MDR-TB. WHO/CDS/TB/2000.279

http://www.who.int/gtb/publications/dotspluspilot-2000-279/english/index.htm

35.   Fixed-Dose Combination Tablets for Treatment of Tuberculosis.WHO/CDS/CPC/TB/99.267 http://www.who.int/gtb/publications/fdc/index.htm

36.   Treatment of Tuberculosis: Guidelines for National Tuberculosis Programmes. WHO/TB/97.220 http://www.who.int/gtb/publications/ttgnp/index.htm

Malaria

37.   New Diagnosis Tests for Malaria. http://mosquito.who.int/cmc_upload/0/000/015/269/ah_diagnostic_jc.pdf

38.   Diagnosis of Malaria. Management of Severe Malaria, a Practical Handbook. http://mosquito.who.int/docs/hbsm.pdf

39.   Malaria Diagnosis. Management of Uncomplicated Malaria and the Use of Antimalarial Drugs. Ch2. http://mosquito.who.int/docs/hbsm.pdf

40.   Malaria Diagnosis New Perspectives.

       http://mosquito.who.int/cmc_upload/0/000/011/403/malaria_diagnosis.pdf

41.   Prevention of Malaria in Pregnancy. Experts Committee report on Malaria - Ch 12.2.6.

http://mosquito.who.int/docs

42.   The Use of Antimalarial Drugs, Report of a WHO Informal Consultation, WHO, Geneva, November 2000.

http://mosquito.who.int/cmc_upload/0/000/014/923/use_of_antimalarials.pdf

43.   Antimalarial Drug Combination Therapy, Report of a WHO Technical Consultation, April 2001. http://mosquito.who.int/cmc_upload/0/000/015/082/use_of_antimalarials2.pdf

44.   WHO Fact Sheet: International price information services - What is WHO Doing to Improve Drug Price Information? August 2002.

http://www.who.int/medicines/organization/par/ipc/drugpriceinfo.shtml

45.   Market News Service. Pharmaceutical Starting Materials/Essential Drugs Report. Geneva, WTO/UNCTAD/International
Trade Centre in Collaboration with WHO. Published monthly. http://www.intracen.org/mns/pharma.html

46.   International Drug Price Indicator Guide on finished products of essential drugs. Management Sciences for Health in
Collaboration with WHO. Published annually. http://www.msh.org

47.   Report of the Workshop on Differential Pricing and Financing of Essential Drugs, World Health Organization and World Trade Organization Secretariats, Norwegian Foreign Affairs Ministry, Global Health Council, 8-11 April 2001, Høsbjør, Norway. http://www.who.int/medicines/library/edm_general/who-wto-hosbjor/wholereporthosbjorworkshop-fin-eng.pdf

48.   Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines. Health Economics and Drugs.
EDM Series No.11. WHO/EDM/PAR/2002.1.

http://www.who.int/medicines/library/par/who-edm-par-2002-1/networktrips.pdf

49.   Implications of the Doha Declaration on the TRIPS Agreement and Public Health. Health Economics and Drugs. EDM
Series No. 12. WHO/EDM/PAR/2002.3. June 2002.

http://www.who.int/medicines/library/docseng_from_a_to_z.shtml#i

50.   WHO Policy Perspectives on Medicines: Globalization, TRIPS and Access to Pharmaceuticals.

No. 3. March 2001 revised. WHO, Geneva

http://www.who.int/medicines/library/edm_general/6pagers/PPM03%20ENG.pdf

51.   Globalization and Access to Drugs: Perspectives on WTO/TRIPS Agreement. Health Economics and Drugs; DAP series No. 7, Revised. WHO, Geneva, 1998. WHO/DAP/98.9.
http://www.who.int/medicines/library/dap/who-dap-98-9-rev/who-dap-98-9.htm

52.   Sources and Prices of Selected  Drugs and Diagnostics for People Living With HIV/AIDS. Joint Project of UNAIDS/UNICEF/WHO-HTP/MSF, May 2002. WHO/EDM/PAR/2002.2.

http://www.who.int/medicines/library/par/hivrelateddocs/prices-eng.pdf

53.   SIBEME: Drug Needs and Costs Quantifying Software (for HIV/AIDS-related drugs): Software User Manual Version 2.0, June 2000. Software available on CD-ROM and diskettes; English and French version. WHO/EDM in collaboration with Eleusis. (Post-testing in progress).

54.   Patent Situation of HIV/AIDS-related Drugs in 80 countries. Geneva, WHO-EDM/UNAIDS, January 2000. http://www.who.int/medicines/library/par/hivrelateddocs/patentshivdrugs.pdf

55.   Manual for Use of a Cost-Effectiveness Tool for Evaluating Anti-Retroviral Drug and Substitute Feeding Interventions to Prevent Mother-to-Child Transmission of HIV. Version 1. Health Strategies International, prepared for UNAIDS, December 1999. http://www.unaids.org/publications/documents/economics/costeffec/
mtct_manual.pdf

56.   Drugs currently available from GDF: First-line anti-tuberculosis drugs, formulations and prices currently supplied/to be supplied by GDF.  

http://www.stoptb.org/GDF/drugsupply/drugs.available.html

57.     How to apply for access to the concessionary prices offered for second-line anti-TB drugs via the Green Light Committee: Instructions for Applying to the Green-Light Committee for Access to Second-Line Anti-Tuberculosis Drugs. WHO/CDS/TB/2001.286 Rev.1

http://www.who.int/gtb/policyrd/PDF/GLC_Application_Instructions.pdf

(dotsplus@who.int for further information).

58.   Gupta R, Kim JY, Espinal MA, et al. Responding to Market Failures in Tuberculosis. Science. 2001. 293:1049-1051.

59.   Laing R O, McGoldrick K. Tuberculosis Drug Issues: Prices, Fixed Dose Combination Products and Second Line Drugs. 26 February 2000.

http://dcc2.bumc.bu.edu/richardl/world_TB_Day/TB_Drug_Issues/
tuberculosis_drug_issues.htm

60.   Procurement of Artemether-Lumefantrine (Coartem®) Through WHO. WHO 2002.

http://mosquito.who.int/cmc_upload/0/000/015/789/CoA_website5.pdf

61.   Health Reform and Drug Financing. Selected Topics. Health Economics and Drugs DAP Series No. 6. WHO/DAP/98.3.

http://www.who.int/medicines/library/dap/who-dap-98-3/who-dap-98-3.htm

62.   Fact Sheet 2002: Meeting the Need. UNAIDS, 2002.

http://www.unaids.org/barcelona/presskit/factsheets/FSresources_en.htm

63.   Paying for HIV/AIDS Services: Lessons from National Health Accounts and Community-Based Health Insurance in Rwanda, 1998 – 1999. UNAIDS Case Study. September 2001. UNAIDS Best Practice Collection.

http://www.unaids.org/publications/documents/economics/families/JC653-Rwanda-E.pdf

64.   Guidelines for Studies of the Social and Economic Impact of HIV/AIDS. September 2000. UNAIDS Best Practice Collection. Key Material. http://www.unaids.org/publications/documents/economics/costeffec/JC326-Guideliens.pdf

65.   WHO Report 2002. Global Tuberculosis Control: Surveillance, Planning, Financing.

http://www.who.int/gtb/publications/globrep02/index.html

66.   What is the GDF? http://www.stoptb.org/GDF/whatis/whatis.html

67.   Lessons from Cost-Recovery in Health. Discussion Paper N2. Forum on Health Sector Reform.

A.Creese and  J.Kutzin. WHO/SHS/NHP/95.5. http://mosquito.who.int/docs

68.   Applying Planned Market Logic to Developing Countries' Health Systems: an Initial Exploration.

Discussion Paper N4. Forum on Health Sector Reform. Richard Saltman. WHO/SHS/95.7.

http://mosquito.who.int/docs

69.   Managing Drug Supply, 2nd Edition. Management Sciences for Health, in Collaboration with WHO. Boston, Kumarian Press, 1997. http://www.msh.org/publications/dmp_pubs.html

70.   Operational Principles for Good Pharmaceutical Procurement (Interagency document). WHO, Geneva, 1999. WHO/EDM/PAR/99.5.

http://www.who.int/medicines/library/par/who-edm-par-99-5/who-edm-par-99-5.htm

71.   Guidelines for Drug Donations (Interagency document). Revised 1999. WHO, Geneva, 1999. WHO/EDM/PAR/99.4.

http://www.who.int/medicines/library/par/who-edm-par-99-4/who-edm-par-99-4.htm

72.   Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies (Interagency document). Geneva, WHO, 1999. WHO/EDM/PAR/99.2.

http://www.who.int/medicines/library/par/who-edm-par-99-2/who-edm-par-99-2.htm

73.   Indicators for Monitoring National Drug Policies: a Practical Manual. Second edition. WHO/EDM/PAR/99.3. http://www.who.int/medicines/library/par/indicators/who_edm_par_993.html

74.   Collaboration Between NGOs, Ministries of Health and WHO in Drug Distribution and Supply. DAP Research Series No. 27. WHO/DAP/98.12.

http://www.who.int/medicines/library/dap/who-dap-98-12/who-dap-98-12.htm

75.   How to Estimate Warehouse Space for Drugs? WHO/DAP/93.3

http://www.who.int/medicines/library/dap/who-dap-93-3/who-dap-93-3.htm.

76.   Fact Sheet 2002: Accelerating Access to Treatment and Care. UNAIDS 2002.

http://www.unaids.org/barcelona/presskit/factsheets/FSaccess_en.htm

77.   Three Million HIV/AIDS Sufferers Could Receive Anti-Retroviral Therapy by 2005. New Hope for Those in Developing World. WHO Press Release 58, 2002

http://www.who.int/mediacentre/releases/who58/en/

78.   Quality Assurance of HIV/AIDS Drugs: Pilot Procurement, Quality and Sourcing Project, including the list of suppliers whose evaluated products are recommended by WHO as being acceptable in principle for procurement by UN Agencies.

http://www.who.int/medicines/organization/par/edl/access-hivdrugs.shtml

79.   HIV Test Kits Bulk Procurement Scheme. http://www.who.int/bct/Main_areas_of_work/BTS/HIV_Diagnostics/
HIV_Test%20Kit_Bulk_Procurement_Scheme.htm

80.   Quality Assurance of HIV Testing. http://www.who.int/bct/Main_areas_of_work/BTS/HIV_Diagnostics/
Quality_Assurance_forHIV_Testing.htm

81.   Report of the Meeting on the Evaluation of the UNAIDS HIV Drug Access Initiative. May 2000. http://www.unaids.org/publications/documents/care/index.html#unaids

82.   Key Elements in HIV/AIDS Care and Support. Geneva, WHO/UNAIDS. A working document, December 2000.

http://www.who.int/HIV_AIDS/HIV_AIDS_Care/Key_elements_HIV_AIDS_care.htm

83.   Voluntary Counselling and Testing for HIV Infection in Antenatal Care. Practical Considerations for
Implementation. HIV/AIDS and Sexually Transmitted Infections Initiative. WHO, Geneva. January 2000. http://www.who.int/HIV_AIDS/ knowledge/implvct3.html

84.   Handbook on Mobilizing NGOs, CBOs and PLHA Groups for Improving Access to Treatment. International HIV/AIDS
Alliance in Collaboration with UNAIDS and WHO-EDM. (final draft).

Tuberculosis

85.   Drugs currently available from GDF: First-line anti-tuberculosis drugs, formulations and prices currently supplied/to be supplied by GDF.  

http://www.stoptb.org/GDF/drugsupply/drugs.available.html

87.   TB Specimen Bank. http://www.who.int/tdr/diseases/tb/specimen.htm